Summary by Cindy Olmstead
In a surprising move, Merck has canceled its COVID-19 vaccine trials and is switching to finding a treatment for the virus. The company said their vaccine candidates did so poorly that it would be better to simply get the virus through natural infection.
Their therapeutic drug candidates, however, are faring better they said. “Interim results from a Phase 3 study showed a greater than 50 percent reduction in the risk of death or respiratory failure in patients hospitalized with moderate to severe COVID-19,” the company’s statement noted of the MK-7110 drug.